Add to ORKGThe invention provides a method for treating cancers that are dependent on cyclin D1 for proliferation, survival, metastasis and differentiation, involving administering effective amount of arsenic trioxide to an affected patient.published_or_final_versio
The present invention provides organic arsenicals which may be used to treat numerous human tumor ce...
The present invention provides organic arsenicals which may be used to treat numerous human tumor ce...
Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds ...
The invention provides a method for treating cancers that are dependent on cyclin Dl for proliferati...
It has been discovered that As2O3 suppresses tyrosine kinase receptors, in particular EGFR and IL-6R...
It has been discovered that As2O3 suppresses tyrosine kinase receptors, in particular EGFR and IL-6R...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cyto...
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cyto...
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cyto...
International audienceArsenic-based drugs were widely used in the treatment of infectious diseases i...
The present invention provides organic arsenicals which may be used to treat numerous human tumor ce...
The present invention provides organic arsenicals which may be used to treat numerous human tumor ce...
Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds ...
The invention provides a method for treating cancers that are dependent on cyclin Dl for proliferati...
It has been discovered that As2O3 suppresses tyrosine kinase receptors, in particular EGFR and IL-6R...
It has been discovered that As2O3 suppresses tyrosine kinase receptors, in particular EGFR and IL-6R...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides an oral formulation of arsenic trioxide (As2O3) for the treatment of ...
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cyto...
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cyto...
The present invention provides organic arsenicals. Many of these compounds have potent in vitro cyto...
International audienceArsenic-based drugs were widely used in the treatment of infectious diseases i...
The present invention provides organic arsenicals which may be used to treat numerous human tumor ce...
The present invention provides organic arsenicals which may be used to treat numerous human tumor ce...
Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds ...